



# “Preaddiction” construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation

Kenneth Blum<sup>1,2</sup>, Igor Elman<sup>3</sup>, Catherine A. Dennen<sup>4</sup>, Thomas McLaughlin<sup>2</sup>, Panayotis K. Thanos<sup>5</sup>, David Baron<sup>1</sup>, Mark S. Gold<sup>6</sup>, Rajendra D. Badgaiyan<sup>7</sup>

<sup>1</sup>Center for Sports and Mental Health, Western University Health Sciences, Pomona, CA, USA; <sup>2</sup>The Kenneth Blum Behavioral and Neurogenetic Institute, LLC, Austin, TX, USA; <sup>3</sup>Department of Psychiatry, Harvard School of Medicine, Cambridge, MA, USA; <sup>4</sup>Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA; <sup>5</sup>Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, USA; <sup>6</sup>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA; <sup>7</sup>Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, Long School of Medicine, University of Texas Health Science Center, San Antonio, TX, USA

*Correspondence to:* Kenneth Blum, PhD, DHL. Center for Sports and Mental Health, Western University Health Sciences, Pomona, CA, USA. Email: drd2gene@gmail.com.

Submitted Aug 19, 2022. Accepted for publication Oct 21, 2022.

doi: 10.21037/atm-2022-32

**View this article at:** <https://dx.doi.org/10.21037/atm-2022-32>

From 1999–2020, over 932,000 Americans died from a drug overdose, and over 564,000 of those deaths involved opioids (1,2). Since 1999, practically every year, excluding 2018, has seen a record-setting number of deaths and overdoses (1–13). According to preliminary data from the Centers for Disease Control and Prevention’s (CDC) National Center for Health Statistics (NCHS), there were approximately 100,306 drug overdose deaths in the United States (US) during a 12-month period that ended in April 2021, which is a 28.5% increase when compared to the 78,056 deaths that occurred during the same period the year before (3). This trend is particularly disturbing given the new drug czar’s projection of the annual number of overdose deaths to reach 165,000 by 2025.

Approximately 9.5 million Americans, aged 12 or older, misused opioids in 2020 (13). In addition, in 2020, approximately 2.5 million Americans, aged 12 or older, suffered from opioid use disorder (OUD), but only about 11% (278,000 individuals) received medication-assisted treatment (13). Untreated individuals are more likely to experience increased criminal activity, HIV infection, and mortality (14). Additionally, it is estimated that these individuals will cost society more than \$500 billion annually (15). Hence, there is a need to revisit our pathophysiological conceptualizations and ensuing therapeutic approaches (16).

As pointed out in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, (DSM-5), substance use disorder (SUD) is defined using 11 equally weighted symptoms of impaired control along a three-stage severity continuum (17). In terms of severity, mild is characterized as having two to three symptoms, moderate as having four to five symptoms, and severe (also commonly referred to as “addiction”) as having six or more symptoms (17). In 2020, 14.5% (40.3 million) of Americans aged 12 or older were diagnosed with SUD. Only 1.4% (4 million) of Americans aged 12 or older received any substance use treatment, and 1% (2.7 million) received substance use treatment at a specialty facility in 2020 (13). In addition, treatment efforts and public health policies have typically focused on those with severe, usually chronic addictions, largely individuals with early-stage SUDs. Although harmful substance misuse and early-stage SUDs can be identified and severity progression monitored, relatively little has been done, especially where it is most prevalent, in mainstream health care settings. In fact, early-stage SUD lacks a broadly accepted term among clinicians or the general public (18).

One of the novel conceptualizations, suggested for inclusion in the DSM, is the “preaddiction” construct, as it is juxtaposed to “prediabetes” (19). The American Diabetes Association defines prediabetes as having abnormal insulin sensitivity (hemoglobin A1c of 5.7–6.4) and/or glucose

tolerance tests [fasting blood glucose of 100–125 mg/dL; oral glucose tolerance test (OGTT) 2-hour blood glucose of 140–199 mg/dL] (20). Prediabetes has a wide range of campaigns and partnerships with third party payors, which over time have contributed to a quantum leap in the efficiency of early detection, shortened delays between symptom onset and treatment entry, and success in halting the progression to diabetes (21). While prediabetes is a manifestation of failing homeostatic function, preaddiction may be linked to closely related (22) hedonostatic derailments (23), namely, hypodopaminergia in the meso- limbic brain reward circuitry (9), as well as the associated opioidergic-, serotonergic-, cannabinergic, GABA-ergic, glutaminergic, and cholinergic abnormalities and clinical manifestations (24,25), collectively termed reward deficiency syndrome (RDS) (24–28).

The implication here is that reward is a key element of mental operation that has evolved beyond immediate survival, and it is crucial for most individual and social activities, including emotional attachments, group affiliations, free will, conformity, and obedience to societal norms and edicts (29–33). Consequently, the lives of individuals with RDS may be intolerable due to their inability to gain full satisfaction from their accomplishments while overcoming the same challenges as others. As a result, they may turn to addictive substance use, which may temporarily alleviate their RDS symptoms but ultimately worsens their clinical condition and pushes them toward eventual full-blown addiction (34,35), which in turn will increase their stress and psychiatric and medical comorbidities (36–38).

RDS encompasses many mental health disorders, characterized by heightened stress, a propensity for the development of addictions, as well as compulsive and impulsive behaviors (39,40). This may be why large-scale genome-wide association studies showed a significant dopaminergic gene risk polymorphic allele overlap between schizophrenic and depressed cohorts (25). A growing body of literature has also identified post-traumatic stress disorder, attention deficit hyperactivity disorder, and spectrum disorders (41,42) as having the typical neurogenetic and psychological RDS underpinnings (43). In addition, several prior studies showed clinical benefit in identifying drug and alcohol risks by utilizing objective DNA polymorphic identification rather than sole reliance on subjective diagnostic surveys (44).

Even though the term “preaddiction” bodes well given the historical advancement of the diabetic field with

prediabetes, scientifically the real evidence resides in concepts related to brain neurotransmitter alterations (e.g., in adolescence as a neurodevelopmental event) referred to as RDS (45). Therefore, we suggest “Reward Deficiency” (namely, lack of normal function) or even “Reward Dysregulation” as a more general term encompassing the nosology of “preaddiction.” In stating this suggestion, we are cognizant that for the lay public, the “preaddiction” terminology may be more recognizable. However, for the clinical and scientific community, reward deficiency/dysregulation may be more parsimonious (46).

Such conceptualization offers immediate benefits in the form of early screening to detect high-risk individuals through the Genetic Addiction Risk Severity (GARS) (19) test and the Reward Deficiency Syndrome Questionnaire (47), which capture both genetic and clinical aspects of RDS (48). Moreover, epigenetic repair may be possible with precision gene-guided therapy using formulations of KB220, a nutraceutical that has demonstrated pro-dopamine regulatory function in animal and human neuroimaging and clinical trials (49), and thus, clinical trials aimed at restoring dopamine homeostasis (i.e., hedonostasis) look promising (50–60).

In sum, we put forward an RDS-derived complementary measure of “preaddiction” that may provide further impetus for the optimal characterization of the construct, including its early detection, staging, and therapeutic management. The heuristic value of our proposal will be determined by its ability to account for specific clinical, genetic, and therapeutic aspects of the preaddiction phenomenon. Further research is warranted to uncover the distinctive aspects of RDS in addictive- *vs.* other psychiatric- and medical conditions and their interactions in the comorbid states (61–64). In essence, our proposal relates to the importance of early genetic testing to identify preaddiction or RDS in children (65,66).

## Acknowledgments

The authors appreciate the expert edits of Margaret A Madigan.

*Funding:* The article was supported in part by R41 MD012318/MD/NIMHD NIH HHS/United States to KB and Marjorie Gondre-Lewis.

## Footnote

*Provenance and Peer Review:* This article was commissioned

by the editorial office, *Annals of Translational Medicine*. The article did not undergo external peer review.

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-2022-32/coif>). KB serves as an unpaid editorial board member of *Annals of Translational Medicine* from September 2022 to August 2024, and is the inventor and holder of all patents related to GARS and KB220. KB has licensed this technology non-exclusively to Victory Nutrition Internationally. The other authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. National Institute on Drug Abuse. Overdose death rates [Internet]. National Institute on Drug Abuse. 2022 [cited 2022 Aug 29]. Available online: <https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates>
2. Death rate maps & graphs [Internet]. Cdc.gov. 2022 [cited 2022 Aug 29]. Available online: <https://www.cdc.gov/drugoverdose/deaths/index.html>
3. Schiller EY, Goyal A, Mechanic OJ. Opioid Overdose. 2022 May 9. In: Stat Pearls. Treasure Island (FL): Stat Pearls Publishing, 2022.
4. Mattson CL, Tanz LJ, Quinn K, et al. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019. *MMWR Morb Mortal Wkly Rep* 2021;70:202–7.
5. Singh GK, Kim IE, Girmay M, et al. Opioid Epidemic in the United States: Empirical Trends, and A Literature Review of Social Determinants and Epidemiological, Pain Management, and Treatment Patterns. *Int J MCH AIDS* 2019;8:89–100.
6. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. *MMWR Morb Mortal Wkly Rep* 2011;60:1487–92.
7. Gladden RM, Martinez P, Seth P. Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013–2014. *MMWR Morb Mortal Wkly Rep* 2016;65:837–43.
8. O'Donnell JK, Gladden RM, Seth P. Trends in Deaths Involving Heroin and Synthetic Opioids Excluding Methadone, and Law Enforcement Drug Product Reports, by Census Region - United States, 2006–2015. *MMWR Morb Mortal Wkly Rep* 2017;66:897–903.
9. O'Donnell JK, Halpin J, Mattson CL, et al. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July–December 2016. *MMWR Morb Mortal Wkly Rep* 2017;66:1197–202.
10. Drug Enforcement Administration. 2019 National Drug Threat Assessment. Drug Enforcement Administration Strategic Intelligence Section, U.S. Department of Justice. Published December 2019. Accessed March 17, 2020. Available online: [https://www.dea.gov/sites/default/files/2020-01/2019-NDTA-final-01-14-2020\\_Low\\_Web-DIR-007-20\\_2019.pdf](https://www.dea.gov/sites/default/files/2020-01/2019-NDTA-final-01-14-2020_Low_Web-DIR-007-20_2019.pdf) pdf icon[PDF]external icon
11. Gladden RM, O'Donnell J, Mattson CL, et al. Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine - 25 States, July–December 2017 to January–June 2018. *MMWR Morb Mortal Wkly Rep* 2019;68:737–44.
12. Kariisa M, Scholl L, Wilson N, et al. Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential - United States, 2003–2017. *MMWR Morb Mortal Wkly Rep* 2019;68:388–95.
13. Breslin M. CDC study shows meteoric rise in number of Americans injecting drugs. *The Hill* [Internet]. 2022 Jul 15 [cited 2022 Sep 22]; Available online: <https://thehill.com/policy/3561018-cdc-study-shows-meteoric-rise-in-number-of-americans-injecting-drugs/>
14. Dydyk AM, Sizemore DC, Haddad LM, et al. NP Safe Prescribing Of Controlled Substances While Avoiding Drug Diversion. 2022 Apr 14. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing, 2022.
15. Key substance use and mental health indicators in the United States: Results from the 2020 national survey on drug use and health [Internet]. *Samhsa.gov*. 2021 [cited 2022 Aug 29]. Available online: <https://www.samhsa.gov>

- gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PD FW102121.pdf
16. Elman I, D'Ambra MN, Krause S, et al. Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes. *Drug Alcohol Depend* 2001;61:163-72.
  17. Ropero-Miller JD, Speaker PJ. The hidden costs of the opioid crisis and the implications for financial management in the public sector. *Forensic Sci Int Synerg* 2019;1:227-38.
  18. Elman I, Howard M, Borodovsky JT, et al. Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone. *Sci Rep* 2020;10:5617.
  19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR (TM)). Arlington, TX: American Psychiatric Association Publishing, 2022.
  20. Edwards D, Roy AK 3rd, Boyett B, et al. Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. *J Addict Sci* 2020;6:1-4.
  21. McLellan AT, Koob GF, Volkow ND. Preaddiction-A Missing Concept for Treating Substance Use Disorders. *JAMA Psychiatry* 2022;79:749-51.
  22. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009;374:1677-86.
  23. Glechner A, Keuchel L, Affengruber L, et al. Effects of lifestyle changes on adults with prediabetes: A systematic review and meta-analysis. *Prim Care Diabetes* 2018;12:393-408.
  24. Elman I, Borsook D. Common Brain Mechanisms of Chronic Pain and Addiction. *Neuron* 2016;89:11-36.
  25. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. *Neuropsychopharmacology* 2006;31:2091-120.
  26. Gold MS, Blum K, Febo M, et al. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems. *Front Biosci (Schol Ed)* 2018;10:309-25.
  27. Elman I, Lowen S, Frederick BB, et al. Functional neuroimaging of reward circuitry responsivity to monetary gains and losses in posttraumatic stress disorder. *Biol Psychiatry* 2009;66:1083-90.
  28. Elman I, Borsook D. The failing cascade: Comorbid post traumatic stress- and opioid use disorders. *Neurosci Biobehav Rev* 2019;103:374-83.
  29. Borsook D, Linnman C, Faria V, et al. Reward deficiency and anti-reward in pain chronification. *Neurosci Biobehav Rev* 2016;68:282-97.
  30. Madigan MA, Gupta A, Bowirrat A, et al. Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence? *Int J Environ Res Public Health* 2022;19:6395.
  31. Elman I, Borsook D, Volkow ND. Pain and suicidality: insights from reward and addiction neuroscience. *Prog Neurobiol* 2013;109:1-27.
  32. Blum K, Siwicki D, Baron D, et al. The benefits of genetic addiction risk score (GARS™) and pro-dopamine regulation in combating suicide in the American Indian population. *J Syst Integr Neurosci* 2018.
  33. Blum K, Gondré-Lewis M, Steinberg B, et al. Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies. *J Syst Integr Neurosci* 2018;4:10.15761/JSIN.1000191.
  34. Blum K, Gondré-Lewis MC, Modestino EJ, et al. Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization. *Mol Neurobiol* 2019;56:7836-50.
  35. Blum K, Modestino EJ, Baron D, et al. Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic. *Curr Psychopharmacol* 2021;10:86-97.
  36. Elman I, Zubieta JK, Borsook D. The missing p in psychiatric training: why it is important to teach pain to psychiatrists. *Arch Gen Psychiatry* 2011;68:12-20.
  37. Blum K, Chen AL, Chen TJ, et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. *Theor Biol Med Model* 2008;5:24.
  38. Elman I, Borsook D. Threat Response System: Parallel Brain Processes in Pain vis-à-vis Fear and Anxiety. *Front Psychiatry* 2018;9:29.
  39. Cadet JL. Epigenetics of Stress, Addiction, and Resilience: Therapeutic Implications. *Mol Neurobiol* 2016;53:545-60.
  40. Sharp BM. Basolateral amygdala and stress-induced hyperexcitability affect motivated behaviors and addiction.



- Transl Psychiatry 2017;7:e1194.
41. Elman I, Upadhyay J, Langleben DD, et al. Reward and aversion processing in patients with post-traumatic stress disorder: functional neuroimaging with visual and thermal stimuli. *Transl Psychiatry* 2018;8:240.
  42. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. *J Psychoactive Drugs* 2000;32 Suppl:i-iv, 1-112.
  43. Comings DE. Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. *Ann N Y Acad Sci* 2001;931:50-83.
  44. Comings DE. Serotonin and the biochemical genetics of alcoholism: lessons from studies of attention deficit hyperactivity disorder (ADHD) and Tourette syndrome. *Alcohol Alcohol Suppl* 1993;2:237-41.
  45. Blum K, Gondre-Lewis MC, Baron D, et al. Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors. *Front Psychiatry* 2018;9:548.
  46. Moran M, Blum K, Ponce JV, et al. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. *Mol Neurobiol* 2021;58:3335-46.
  47. Koob GF, Le Moal M. Addiction and the brain antireward system. *Annu Rev Psychol* 2008;59:29-53.
  48. Febo M, Blum K, Badgaiyan RD, et al. Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome. *Front Biosci (Landmark Ed)* 2017;22:669-91.
  49. Kótyuk E, Urbán R, Hende B, et al. Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29). *J Psychopharmacol* 2022;36:409-22.
  50. Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency syndrome. *Am J Med Genet B Neuropsychiatr Genet* 2005;132B:29-37.
  51. Fried L, Modestino EJ, Siwicki D, et al. Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair. *Curr Pharm Biotechnol* 2020;21:528-41.
  52. Vereczkei A, Barta C, Magi A, et al. FOXN3 and GDNF Polymorphisms as Common Genetic Factors of Substance Use and Addictive Behaviors. *J Pers Med* 2022;12:690.
  53. White O, Roeder N, Blum K, et al. Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review. *Int J Environ Res Public Health* 2022;19:9477.
  54. Blum K, McLaughlin T, Bowirrat A, et al. Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"? *J Pers Med* 2022;12:321.
  55. Blum K, Brodie MS, Pandey SC, et al. Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation. *J Pers Med* 2022;12:1009.
  56. Gupta A, Bowirrat A, Gomez LL, et al. Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors. *Int J Environ Res Public Health* 2022;19:552.
  57. Rapp C, Hamilton J, Blum K, et al. The long-term interaction of diet and dopamine D2 gene expression on brain microglial activation. *Psychiatry Res Neuroimaging* 2022;320:111430.
  58. Richardson B, Swenson S, Hamilton J, et al. Chronic neuroleptic treatment combined with a high fat diet elevated [3H] flunitrazepam binding in the cerebellum. *Prog Neuropsychopharmacol Biol Psychiatry* 2022;112:110407.
  59. Richer K, Hamilton J, Delis F, et al. Chronic treatment and abstinence from methylphenidate exposure dose-dependently changes glucose metabolism in the rat brain. *Brain Res* 2022;1780:147799.
  60. Nami M, Thatcher R, Kashou N, et al. A Proposed Brain-, Spine-, and Mental- Health Screening Methodology (NEUROSCREEN) for Healthcare Systems: Position of the Society for Brain Mapping and Therapeutics. *J Alzheimers Dis* 2022;86:21-42.
  61. Blum K, Soni D, Badgaiyan RD, et al. Overcoming reward deficiency syndrome by the induction of "dopamine homeostasis" instead of opioids for addiction: illusion or reality? *J Osteopath Med* 2022;122:333-7.
  62. Braverman ER, Dennen CA, Gold MS, et al. Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis". *Int J Environ Res Public Health* 2022;19:5480.
  63. Renard J, Rosen LG, Loureiro M, et al. Adolescent Cannabinoid Exposure Induces a Persistent Sub-Cortical Hyper-Dopaminergic State and Associated Molecular

- Adaptations in the Prefrontal Cortex. *Cereb Cortex* 2017;27:1297-310.
64. Novi M, Paraskevopoulou M, Van Rooij D, et al. Effects of substance misuse and current family history of substance use disorder on brain structure in adolescents and young adults with attention-deficit/hyperactivity disorder. *Drug Alcohol Depend* 2021;228:109032.
65. File D, Bõthe B, File B, et al. The Role of Impulsivity and Reward Deficiency in "Liking" and "Wanting" of Potentially Problematic Behaviors and Substance Uses. *Front Psychiatry* 2022;13:820836.
66. Blum K, Gardner E, Oscar-Berman M, et al. "Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. *Curr Pharm Des* 2012;18:113-8.

**Cite this article as:** Blum K, Elman I, Dennen CA, McLaughlin T, Thanos PK, Baron D, Gold MS, Badgaiyan RD. "Preaddiction" construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation. *Ann Transl Med* 2022;10(21):1181. doi: 10.21037/atm-2022-32